Is a 30G needle the right choice for drawing cagrilintide at 10 mg/mL?

Stated plainly: a 30G needle · cagrilintide · 10 mg/mL.

Both of these get recommended confidently by different people, which suggests neither is obviously right.

My constraints are cost, measurement resolution and how much handling I am prepared to do — in roughly that order.

What is the actual trade-off, and does it matter at the scale I am working at?

At 10 mg/mL a 1 mg dose is 0.1 mL — 10 units on a U-100 barrel — and no needle gauge changes that number. Gauge changes three other things: how long the draw takes, how much stays behind in the hub, and how much rubber you core out of the stopper. On the 30G scale a larger number is a finer needle, so a 30G needle is fine enough that a viscous solution draws slowly and a hurried draw pulls bubbles. If you are drawing 10 units at a time, the dead space matters more than the bore: a fixed-needle barrel loses microlitres, a luer hub loses tens of them, and at 10 mg/mL each microlitre is 10 µg.

Start with the fact that gauge numbers run backwards — a higher number is a thinner needle — which is the source of half the confusion in this tag.

For injecting, 29G to 31G is the usual range and the difference in perceived discomfort between them is small. Needle length matters more than gauge for comfort at these volumes.

Flow through a needle scales with the fourth power of the internal radius under the Hagen–Poiseuille relation. Halving the radius reduces flow sixteen-fold at the same pressure, which is why a 31G needle draws so much more slowly than a 21G.

Coring risk as a function of needle gauge and insertion technique is documented in pharmacy compounding guidance.

Gauge numbers run backwards. Higher number, thinner needle.

The short version: 21G to 23G to draw, 29G to 31G to inject, and never the same needle for both.

Typical outer diameters: 21G is about 0.82 mm, 23G about 0.64 mm, 25G about 0.51 mm, 29G about 0.34 mm and 31G about 0.26 mm. The gauge number and the diameter move in opposite directions.

Drawing a viscous or foamy solution through a fine needle takes long enough that people rush the plunger, which causes more foaming. Using a wider drawing needle is the fix.

Butyl rubber closures are specified for resealing after piercing up to a stated gauge, which is the basis for the fine-gauge repeated-entry practice.

Nothing here is medical advice.

Flow goes as the fourth power of radius. That is why the difference feels so large.

Answering this needs to know the viscosity of what is being drawn, since a viscous solution through a fine needle is slow enough to encourage bad technique.

A 30G or 31G needle through a butyl stopper leaves a track that reseals, which is why fine-gauge repeated entry is tolerable and coarse-gauge repeated entry is not.

It helps to be literal here: stopper coring — punching a disc of rubber into the solution — is a large-bore phenomenon. An 18G or 21G needle inserted straight and fast is the classic way to do it; inserting at a slight angle with the bevel up reduces the risk.

Needle gauge to outer diameter correspondence is standardised and published; the inverse relationship between gauge number and diameter is the reason for the counter-intuitive labelling.

Angle the bevel and insert gently to avoid coring the stopper.

It helps to be literal here: for a 4 mm pen-style needle the gauge options are narrow and the choice is nearly made for you.

Fixed-needle insulin syringes are supplied in 29G to 31G and cannot be swapped for drawing, which is the trade-off against their much lower dead space.

The Hagen–Poiseuille relation gives flow proportional to the fourth power of radius, which is the quantitative basis for every gauge recommendation here.

If a solution will not draw through a 25G needle, the problem is the solution rather than the needle.

Length affects comfort more than gauge does at these volumes.

The honest answer is that injection gauge is a comfort decision and drawing gauge is a stopper-coring decision.

Very fine needles are more prone to bending and to blocking with any particulate, which is a practical argument for inspecting the solution before drawing.

The general principle here — that peptides adsorb and denature at air–liquid and solid–liquid interfaces — is standard formulation science, and it is why licensed presentations contain a surfactant such as polysorbate 20 or 80. A research vial does not, which is precisely why handling matters more, not less.

The caveat is that no gauge choice makes a non-sterile preparation safe, and research-use compounds are not approved for human use.

Big to draw, small to inject, never the same one twice.